

Total Intravenous Anesthesia: Theoretical Foundation and Practical Considerations

Talmage D. Egan, M.D.
University of Utah School of Medicine

© Talmage D. Egan
October 21st, 2022



Disclosures

In the last 2 years, Dr. Egan has the following industry relationships to disclose:

- Founder and equity partner: Medvis
- Research support: Medtronic
- Scientific Advisory Board Member: Acacia Pharma

TAKE **5** FOR **TIVA**



THRIVE

TAKE **5** FOR TIVA

(Brief introduction to TIVA theory and practice...)

Outline

- TIVA vs Inhaled Anesthesia from a Drug Delivery Perspective
- Posological Considerations in TIVA
 - A Venn diagram
 - A surfing analogy
 - 3 practice domains
- ~~Pharmacokinetic/Dynamic Models and Simulation Applied to TIVA~~
- “Must Know” Pharmacokinetic/Dynamic Attributes of TIVA Drugs
- Propofol & Opioid Kinetics and TIVA
- Tips and Tricks for TIVA


TAKE **5** FOR TIVA


Overall Goal

Establish the scientific and practical foundation upon which to base a TIVA practice.

TAKE **5** FOR **TIVA**

University of Utah Department of Anesthesiology General Anesthetic Technique (May 2014–June 2022)







TIVA vs Inhaled Drug Delivery

Gaining access to the circulation via the lung affords fundamental advantages that have set a standard for innovation in TIVA practice since the mid 1990s.

TAKE **5** FOR **TIVA**

Drug Delivery: TIVA vs. Inhaled (Circa 1990s)

Access to Circulation



Accurate Administration



Pharmacokinetic Exactness



Pharmacodynamic Exactness



Egan (*J Clin Anesth* 1996)

Anesthesia Posology

Anesthesia posology (the study of drug dosing) is fundamentally different than other specialties of medicine.

TAKE 5 FOR TIVA

Getting the dose right: anaesthetic drug delivery and the posological sweet spot

K. Kuck* and T. D. Egan

Department of Anesthesiology, University of Utah School of Medicine

*Corresponding author. E-mail: kai.kuck@hsc.utah.edu

A last try at popularizing the term “posology...”

Posology, a scientific term not in common usage, is the science of drug dosage; it is thus a branch of clinical pharmacology (or perhaps a synonym of sorts). Combining the Greek words *posos* (how much) and *logos* (science), posology can be thought of more simply as ‘dosology’. In the posology of anaesthesia, a fundamental question anaesthetists must answer early in the process is ‘What is the right anaesthetic dosing strategy for this patient?’

In this issue of the *British Journal of Anaesthesia*, van Oort RP and colleagues¹ report a novel approach to optimizing anaesthesia. Their study was an attempt to personalize target-controlled infusion (TCI) therapy with a single observation from the patient. Taking a Bayesian approach, the authors


started with pharmacokinetic (PK) parameters from a population model² and then adjusted them based on the difference between

“Combining the Greek words ‘posos’ (how much) and ‘logos’ (science), posology can be thought of more simply as ‘dosology’.”

the observation, normalized by their variability. This moves the adjusted system from the *a priori* starting point

Kuck & Egan (*Br J Anaesth* 2017)


General Approach to Anesthesia Posology



Egan (*Anesth Analg* 2018)


Posology in Anesthesia: A Venn Diagram

Most Therapeutic Areas



Kuck & Egan (*Br J Anaesth* 2017)

Anesthesia Therapeutics




TAKE 5 FOR TIVA

Anesthesia Posology

A surfing analogy is helpful in understanding the modern approach to anesthesia posology.

TAKE 5 FOR TIVA

Posology in Anesthesia: A Surfing Analogy



TAKE 5 FOR TIVA


Egan & Shafer (Anesthesiology 2003)

TIVA Practice Domains

There are three TIVA practice domains (i.e., dose, concentration, & effect). The effect domain is optimal.

TAKE 5 FOR TIVA

Three TIVA Practice Domains




TAKE 5 FOR TIVA

Egan (*Anesth Analg* 2018)

The Dose Domain



- ✓ Simple to use
- ✓ Familiar to all



- ✓ Ignores temporal changes
- ✓ Slow to steady-state
- ✓ Ignores intersubject variability


TAKE 5 FOR TIVA

Egan (*Anesth Analg* 2018)

The Concentration Domain



- ✓ Automates dosage calculations
- ✓ Accounts for temporal changes
- ✓ Quick to steady-state
- ✓ Accounts for co-variate effects (PK)



- ✓ Ignores intersubject variability
- ✓ Less familiar (USA)


TAKE 5 FOR TIVA

Egan (*Anesth Analg* 2018)

The Effect Domain



- ✓ Automates dosage calculations
- ✓ Accounts for temporal changes
- ✓ Quick to steady-state
- ✓ Accounts for co-variate effects (PKPD)
- ✓ Accounts for intersubject variability




- ✓ Complicated control system (automated)
- ✓ Suboptimal sensors
- ✓ Less familiar
- ✓ Unintended consequences?

Usually Best!

TAKE 5 FOR TIVA

Most important!

Egan (*Anesth Analg* 2018)




Crucial Drug Behaviors and TIVA

Certain pharmacokinetic attributes inform TIVA posology for bolus and infusions conditions. These attributes are best understood through PK-PD simulation.

TAKE 5 FOR TIVA


Clinical Inference via PK/PD Simulation



TAKE 5 FOR TIVA


Obara & Egan
(in Hemmings & Egan, Elsevier 2019)

Bolus Front-End & Back-End




TAKE 5 FOR TIVA

Infusion Front-End




TAKE 5 FOR TIVA

Infusion Back-End




TAKE 5 FOR TIVA

Impact of Infusion Duration




TAKE 5 FOR TIVA

Impact of Infusion Duration



TAKE 5 FOR TIVA

75% Decrement Times




Crucial Drug Behaviors and TIVA

Certain pharmacodynamic concepts inform TIVA posology. Chief among these are propofol-opioid pharmacodynamic interactions.

TAKE 5 FOR TIVA


MAC Reduction by Opioids



TAKE 5 FOR TIVA

Ogura & Egan (in Hemmings & Egan, Elsevier 2019)


Propofol Cp50 Reduction by Opioids



TAKE 5 FOR TIVA

Ogura & Egan (in Hemmings & Egan, Elsevier 2019)


Propofol-Opioid PD Interaction



TAKE 5 FOR TIVA

Ogura & Egan (in Hemmings & Egan, Elsevier 2019)


Propofol-Opioid PD Interaction



TAKE 5 FOR TIVA

Ogura & Egan (in Hemmings & Egan, Elsevier 2019)


Propofol-Opioid PD Interaction



TAKE 5 FOR TIVA

Ogura & Egan (in Hemmings & Egan, Elsevier 2019)


Propofol-Opioid PD Interaction



TAKE 5 FOR TIVA

Ogura & Egan (in Hemmings & Egan, Elsevier 2019)


Propofol-Opioid PD Interaction



TAKE 5 FOR TIVA


Ogura & Egan (in Hemmings & Egan, Elsevier 2019)

Propofol-Opioid PD Interaction



TAKE 5 FOR TIVA

Propofol-Opioid PD Interaction



- 1 Opioids reduce Cp_{50} synergistically.
- 2 Cp_{50} reduction is substantial (75%+).
- 3 Most Cp_{50} reduction occurs at moderate opioid levels.
- 4 Cp_{50} reduction is not complete.
- 5 An infinite number of hypnotic-opioid combinations achieve Cp_{50} .

TAKE 5 FOR TIVA

Ogura & Egan (in Hemmings & Egan, Elsevier 2019)


Propofol Clinical Pharmacology & TIVA

Simulation of propofol's pharmacokinetic behavior helps inform posological decisions in TIVA.

TAKE 5 FOR TIVA


TAKE 5 FOR TIVA

Bolus Front-End & Back-End




TAKE 5 FOR TIVA

Infusion Front-End




TAKE 5 FOR TIVA

Impact of Loading Dose





TAKE 5 FOR TIVA

Infusion Back-End



Impact of Infusion Duration






Opioid Clinical Pharmacology & TIVA


Simulation of remifentanyl and fentanyl pharmacokinetic behavior helps inform posological decisions in TIVA.

Bolus Front-End & Back-End




TAKE 5 FOR TIVA

Infusion Front-End




TAKE 5 FOR TIVA

Infusion Back-End




Context Sensitive Half-Time




Egan et al (Anesthesiology 1993)


Impact of Infusion vs. Bolus



Disruptive Impact of Boluses



Transition Opioid




TAKE 5 FOR TIVA

Tips and Tricks of the TIVA Trade


Certain practical tips are helpful for successful TIVA practice.

TAKE 5 FOR TIVA

Infuse Close and Secure




Infuse Close to IV




Do **Not** Infuse Far from IV

TAKE **5** FOR **TIVA**

Keep IV Visible




IV Visible: Optimal




IV **Not** Visible: Suboptimal

TAKE **5** FOR **TIVA**

Be Alert for Infusion Disruption




IV Flowing




IV Kinked, **Not** Flowing

TAKE **5** FOR **TIVA**

Check for Pump Programming Error




Typical Rate = 10-20 ml/Hr




Typical Rate = 40-60 ml/Hr

Consider Using EEG



TAKE **5** FOR TIVA


Check Infusions Frequently




TAKE **5** FOR TIVA

Consider Real Time PK/PD Simulation

Simulation suggests time to stop infusion.




Pharmacokinetic Simulation




TAKE **5** FOR **TIVA**

Adjust Dose for Senior Patients

Older patients will require lower doses.




Pharmacokinetic Simulation




TAKE **5** FOR **TIVA**

Impact of Age




Obara & Egan (in Hemmings & Egan, Elsevier 2019)

Adjust Pump Weight Setting for Obese Patients



TAKE 5 FOR TIVA


Impact of Body Weight



TAKE 5 FOR TIVA


Obara & Egan (in Hemmings & Egan, Elsevier 2019)

Deepen Anesthesia with Small Bolus and Infusion Rate Increase





TAKE 5 FOR TIVA

Impact of Bolus & Infusion




TAKE 5 FOR TIVA





THRIVE

Supplementary Material



Target Controlled Infusion Practice

Prior knowledge:


- Pharmacologic models
- Therapeutic windows
- Covariate effects




Current knowledge:

- Real-time assessment


Standard Monitor



Pharmacokinetic Simulation




Electronic Assessment



To operate:

- Select pharmacokinetic model
- Input covariates
- Choose effect-site or plasma control
- Designate/adjust target concentration



Clinical Assessment

Open Loop Control

TAKE 5 FOR TIVA

Egan et al (Br J Anaesth 2020)